The innovation-complexity paradox in life sciences
The pharmaceutical industry is facing a defining paradox: the therapies that hold the greatest promise, like bispecific antibodies (BsAbs), also carry the greatest complexity. As biologics evolve, BsAbs are leading a new wave of therapeutic innovation, unlocking novel mechanisms of action and targeting precision. But they also expose critical challenges in R&D, manufacturing, regulatory strategy, and clinical development.
This new Clarivate report, The Innovation-Complexity Paradox in Life Sciences, uses BsAbs as a lens to examine the shifting landscape of drug development. Once considered niche, BsAbs are now a $15 billion market with more than 200 active clinical programs. Their rise signals both opportunity and disruption for developers across oncology, autoimmune diseases, and beyond.
Inside the report:
- Targeting innovation: How BsAbs enable dual-target therapies and help overcome treatment resistance
- Development risk: Navigating cytokine release syndrome (CRS), ICANS, chain mispairing, and more
- Production complexities: Exploring why BsAb manufacturing costs 40% more than monoclonals and how tech platforms are adapting
- Regulatory landscape: How global uncertainty is shaping development timelines and approval strategies
- Strategic moves: M&A, licensing, and partnerships driving the competitive BsAb arms race
- The road ahead: What BsAbs reveal about the future of personalized medicine and biologics innovation
Download the full report today.
This report integrates proprietary data from Clarivate’s trusted platforms:
- BioWorld – Real-time biotech and regulatory news
- Cortellis Deals Intelligence – Insights on partnerships, M&A, and valuations
- Cortellis Competitive Intelligence – Pipeline, IP, and market strategy tracking
- Cortellis Clinical Trials Intelligence – Global trial data and protocol analytics
- OFF-X – Predictive safety intelligence to reduce development risk
